Eagle Pharmaceuticals (EGRX) Competitors $1.50 -0.35 (-18.92%) As of 04/8/2025 03:40 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsSustainabilityTrendsBuy This Stock EGRX vs. MGX, GANX, ALGS, ADAP, KRON, ATNM, TNYA, FBRX, SKYE, and BDRXShould you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include Metagenomi (MGX), Gain Therapeutics (GANX), Aligos Therapeutics (ALGS), Adaptimmune Therapeutics (ADAP), Kronos Bio (KRON), Actinium Pharmaceuticals (ATNM), Tenaya Therapeutics (TNYA), Forte Biosciences (FBRX), Skye Bioscience (SKYE), and Biodexa Pharmaceuticals (BDRX). These companies are all part of the "pharmaceutical products" industry. Eagle Pharmaceuticals vs. Metagenomi Gain Therapeutics Aligos Therapeutics Adaptimmune Therapeutics Kronos Bio Actinium Pharmaceuticals Tenaya Therapeutics Forte Biosciences Skye Bioscience Biodexa Pharmaceuticals Eagle Pharmaceuticals (NASDAQ:EGRX) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings. Does the media refer more to EGRX or MGX? In the previous week, Metagenomi had 6 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 7 mentions for Metagenomi and 1 mentions for Eagle Pharmaceuticals. Metagenomi's average media sentiment score of 0.49 beat Eagle Pharmaceuticals' score of 0.00 indicating that Metagenomi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eagle Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Metagenomi 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, EGRX or MGX? Eagle Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Metagenomi has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500. Does the MarketBeat Community prefer EGRX or MGX? Eagle Pharmaceuticals received 391 more outperform votes than Metagenomi when rated by MarketBeat users. However, 95.45% of users gave Metagenomi an outperform vote while only 66.03% of users gave Eagle Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEagle PharmaceuticalsOutperform Votes41266.03% Underperform Votes21233.97% MetagenomiOutperform Votes2195.45% Underperform Votes14.55% Do insiders and institutionals have more ownership in EGRX or MGX? 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has better valuation & earnings, EGRX or MGX? Eagle Pharmaceuticals has higher revenue and earnings than Metagenomi. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEagle Pharmaceuticals$257.55M0.08$35.64MN/AN/AMetagenomi$52.30M1.00-$68.25M-$2.62-0.53 Is EGRX or MGX more profitable? Eagle Pharmaceuticals has a net margin of 0.00% compared to Metagenomi's net margin of -134.27%. Eagle Pharmaceuticals' return on equity of 0.00% beat Metagenomi's return on equity.Company Net Margins Return on Equity Return on Assets Eagle PharmaceuticalsN/A N/A N/A Metagenomi -134.27%-43.23%-18.86% Do analysts rate EGRX or MGX? Metagenomi has a consensus target price of $13.00, suggesting a potential upside of 828.57%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than Eagle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Metagenomi 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryEagle Pharmaceuticals beats Metagenomi on 9 of the 16 factors compared between the two stocks. Remove Ads Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EGRX vs. The Competition Export to ExcelMetricEagle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.48M$6.08B$5.08B$6.91BDividend YieldN/A2.90%5.34%4.22%P/E RatioN/A6.5321.3217.05Price / Sales0.08185.43345.2285.96Price / Cash0.4065.6738.1534.64Price / BookN/A5.356.023.66Net Income$35.64M$141.19M$3.19B$247.27M7 Day Performance-3.23%-12.28%-8.86%-9.80%1 Month Performance76.47%-20.11%-6.83%-12.84%1 Year Performance-69.70%-22.71%0.66%-10.68% Eagle Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EGRXEagle PharmaceuticalsN/A$1.50-18.9%N/A-70.0%$19.48M$257.55M0.00100Analyst ForecastGap DownMGXMetagenomi1.7562 of 5 stars$1.36-8.1%$14.40+958.8%-85.8%$50.84M$52.30M-0.52236Analyst RevisionGap DownGANXGain Therapeutics2.9976 of 5 stars$1.91+1.1%$8.20+329.3%-53.9%$50.66M$50,000.00-1.7420Gap UpALGSAligos Therapeutics3.6639 of 5 stars$8.25-9.5%$70.00+748.5%-82.4%$50.44M$3.95M-0.6290Gap UpADAPAdaptimmune Therapeutics2.2258 of 5 stars$0.20-4.4%$1.93+879.7%-83.4%$50.41M$178.03M-0.90490Analyst ForecastGap UpKRONKronos Bio3.6055 of 5 stars$0.83flat$1.63+97.0%-37.1%$50.30M$9.85M-0.58100ATNMActinium Pharmaceuticals1.8717 of 5 stars$1.61-11.0%$7.40+359.6%N/A$50.23M$81,000.00-1.1630News CoverageGap DownTNYATenaya Therapeutics3.7424 of 5 stars$0.57-11.3%$6.25+996.3%-91.0%$49.93MN/A-0.40110Gap UpFBRXForte Biosciences2.6361 of 5 stars$7.76-5.4%$23.58+203.9%+19,728.8%$49.61MN/A-0.485Analyst RevisionNews CoverageGap UpSKYESkye Bioscience1.0258 of 5 stars$1.59-15.0%$18.00+1,032.1%-87.5%$49.25MN/A-2.2111Gap UpHigh Trading VolumeBDRXBiodexa Pharmaceuticals0.1488 of 5 stars$1.32+7.3%N/AN/A$48.24M$83,000.000.0020Gap Down Remove Ads Related Companies and Tools Related Companies MGX Alternatives GANX Alternatives ALGS Alternatives ADAP Alternatives KRON Alternatives ATNM Alternatives TNYA Alternatives FBRX Alternatives SKYE Alternatives BDRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EGRX) was last updated on 4/9/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Silver isn't just a safe haven for your wealth—it's a critical resource in the global tech and energy race. Wi...GoldenCrest Metals | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredThinking of buying Nvidia? Read this firstI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EGRX Stock Free EGRX Stock Alerts